Supplementary Figure 7: Combined pSTAT5 / RELA ratio and total pSTAT5 levels correlate best with survival and remission duration in patients with B-NOS progenitor B-ALL
From: Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival
(a) Survival of B-NOS B-ALL patients stratified by pSTAT5 and the ratio of pSTAT5 to RELA. (b) Overall survival of B-NOS B-ALL patients that were stratified based on pSTAT5 / RELA ratio alone. (c) Overall survival of B-NOS B-ALL patients that were separated into two equal-sized groups based on low or high pSTAT5 levels. (d,e) Overall survival of B-NOS B-ALL patients that were stratified by separating them based on pSTAT5 / RELA ratio (low or high) and then further subdividing those groups based pSTAT5 levels (low or high). (f) Remission duration of B-NOS B-ALL patients stratified by pSTAT5 and the ratio of pSTAT5 to RELA. (g) Remission duration of B-NOS B-ALL patients that were stratified based on pSTAT5 / RELA ratio alone: low or high. (h) Remission duration of B-NOS B-ALL patients that were separated into two equal-sized groups based on low or high pSTAT5 levels. (I,j) Remission duration of B-NOS B-ALL patients that were stratified by separating them based on pSTAT5 / RELA ratio (low or high) and then further subdividing those groups based pSTAT5 levels (low or high). (k) Statistical summary of the results shown in panels (b-e) and (g-j). N.D. = not done. P-values determined by log-rank test for trends (a, f) or log-rank Mantle-Cox test (b,c,d,e,g,h,i,j).
